Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name TH-4000
Synonyms
Therapy Description

TH-4000 (tarloxotinib) is a prodrug that is converted to an irreversible Egfr/Erbb2 (Her2)/Erbb4 inhibitor under hypoxia, potentially resulting in inhibition of tumor cell growth (PMID: 33355298).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TH-4000 PR610|Hypoxin|TRLX|Tarloxotinib bromide|Tarloxotinib EGFR Inhibitor (Pan) 61 HER2 Inhibitor 41 TH-4000 (tarloxotinib) is a prodrug that is converted to an irreversible Egfr/Erbb2 (Her2)/Erbb4 inhibitor under hypoxia, potentially resulting in inhibition of tumor cell growth (PMID: 33355298).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01631279 Phase Ib/II TH-4000 A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors Terminated USA | NZL 0
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated USA | AUS 0
NCT02454842 Phase II TH-4000 Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC Terminated USA | AUS 0
NCT03805841 Phase II TH-4000 Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN) Terminated USA | CAN 1


Additional content available in CKB BOOST